Publications by authors named "I Piseddu"
Background And Aims: The outcome of patients with HCC who achieved complete response (CR) to immune-checkpoint inhibitor (ICI)-based systemic therapies is unclear.
Approach And Results: Retrospective study of patients with HCC who had CR according to modified Response Evaluation Criteria in Solid Tumors (CR-mRECIST) to ICI-based systemic therapies from 28 centers in Asia, Europe, and the United States. Of 3933 patients with HCC treated with ICI-based noncurative systemic therapies, 174 (4.
Article Synopsis
- Checkpoint inhibitor-induced steroid-refractory (sr) and steroid-dependent (sd) immune-related adverse events (irAE) affect around 11% of patients, resulting in worse outcomes and no established second-line treatments from prospective trials.* -
- A study compared the efficacy of extracorporeal photopheresis (ECP) with second-line immunosuppressants (SLI) in 21 patients suffering from sr/sd-irAE, showing ECP had a higher clinical response (93% vs. 80%) and better quality of life scores.* -
- Results indicated that ECP patients experienced longer overall survival (23 months vs. 12 months) and lower cancer progression rates, suggesting ECP as a
Purpose: To assess immunogenic effects in unembolized contralateral tumor after single lobar yttrium-90 transarterial radioembolization (Y-TARE) of colorectal liver metastases (CRLMs).
Material And Methods: The analysis comprised 10 patients with microsatellite stable (MSS) CRLM scheduled for staged treatment in the prospective AROMA trial. Eligibility criteria included bilobar metastatic disease with >5 lesions without any treatment within 3 weeks.
Background: Immune checkpoint inhibitor (ICI)-induced myocarditis is a rare immune-related adverse event (irAE) with a fatality rate of 40%-46%. However, irMyocarditis can be asymptomatic. Thus, improved monitoring, detection and therapy are needed.
View Article and Find Full Text PDFArticle Synopsis
- A study evaluated the efficacy and safety of first-line therapies for hepatocellular carcinoma (HCC), specifically comparing atezolizumab/bevacizumab (atezo/bev) and lenvatinib, focusing on bleeding and thromboembolic events.
- A total of 464 patients from seven centers in Germany and Austria were analyzed, revealing that bleeding and thromboembolic events occurred in similar rates for both treatments within 6 months.
- The findings suggest that safety concerns regarding bleeding and thromboembolic events might not significantly influence clinical decisions when selecting between atezo/bev and lenvatinib for HCC treatment.*